SIETES :: 93213 citas

Resultados de la búsqueda por OFTALMOLOGÍA REFINAR BÚSQUEDA

1.

Kurian A, Reghunadhan I, Thilak P, Soman I, Nair U. Short-term efficacy and safety of topical ß-blockers (timolol maleate ophthalmic solution, 0.5%) in acute migraine. A randomized crossover trial. Jama Ophthalmol 2020;138:1 de octubre. [Ref.ID 103736]

2.

Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020;77:agosto. [Ref.ID 103656]

3.

Boulware DR, Pullen MF, Bangdiwala AS, Pastik KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, et al.. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19. N Engl J Med 2020;383:3 de junio. [Ref.ID 103646]

4.

Yang M-S, Lee JY, Kim J, Kim G-W, Kim B-K, Kim Y, Park H-W, Cho S-H, Min K-U, Kang H-R. Searching for the culprit drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea. J Allergy Clin Immunol 2020;8:febrero. [Ref.ID 103535]

5.

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]

6.

Anónimo. Troubles rétiniens d'origine médicamenteuse. Prescrire 2019;39:19-25. [Ref.ID 103005]

7.

Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]

8.

Belmonte E, Bernardo A. 18 médicos recibieron más de 50.000 euros cada uno de una sola farmacéutica en 2017 . eldiario.es 2018:10 de octubre. [Ref.ID 102835]

9.

Anónimo. FDA approval of cenegermin marks three firsts in drug history . DIA Daily 2018:24 de agosto. [Ref.ID 102813]

10.

Anónimo. Conjonctivites présumées bactériennes. Prescrire 2018;38:361-5. [Ref.ID 102660]

11.

The Dry Eye Assessment and Management Study Research Group. n-3 fatty acid supplementation for the treatment of dry eye disease. N Engl J Med 2018;378:3 de mayo. [Ref.ID 102592]

12.

Rabin JC, Karunathilake N, Patrizi K. Effects of milk vs dark chocolate consumption on visual acuity and contrast sensitivity within 2 hours. A randomized clinical trial. Jama Ophthalmol 2018;136:678-81. [Ref.ID 102572]

13.

Anónimo. FDA received more reports last year of “rare, frightening side effect” of aflibercept. DIA Daily 2018:4. [Ref.ID 102459]

14.

Uyhazi KE, Miano T, Pan W, VanderBeek BL. Association of novel oral antithrombotics with the risk of intraocular bleeding. Jama Ophthalmol 2017:14 de diciembre. [Ref.ID 102190]

15.

Tricco AC, Thomas SM, Veroniki AA, Hamid JS, Cogo E, Strifler L, Khan PA, Robson R, Sibley KM, MacDonald H, Riva JJ, Thavorn K, Wilson C, Holroyd-Leduc J, Kerr GD, Feldman F, Majumdar SR, Jaglal SB, Hui W, Straus SE. Comparisons of interventions for preventing falls in older adults. A systematic review and meta-analysis. JAMA 2017;318:1687-99. [Ref.ID 102139]

16.

Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology 2017:5 de septiembre. [Ref.ID 102058]

17.

Silverman E. Allergan’s deal with the Mohawks raises troubling questions about the future of generics. STAT 2017:1. [Ref.ID 102047]

18.

Shanthanna H, Gilron I, Rajarathinam M, AlAmri R, Kamath S, Thabane L, Devereaux PJ, Bhandari M. Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trialsBenefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. PLOS Medicine 2017:15 de agosto. [Ref.ID 102020]

19.

Anónimo. Ranibizumab, bévacizumab ou aflibercept par voie intravitréenne: thromboses. Prescrire 2017;37:509-11. [Ref.ID 102009]

20.

Becker C, Jick SS, Meier CR. Selective serotonin reuptake inhibitors and cataract risk: a case-control analysis. Ophthalmology 2017;124:. [Ref.ID 101923]